Mumbai, Oct 3: Wockhardt, a leading Indian pharmaceutical company, has achieved a major breakthrough with the development of Zaynich, a new antibiotic targeting multi-drug-resistant (MDR) Gram-negative bacteria that resist existing treatments. The drug combines cefepime and zidebactam, offering a potent new option against dangerous pathogens such as E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter species.
Bacterial drug resistance has become a global health emergency, as infections increasingly fail to respond to available antibiotics. Zaynich represents a significant advancement for India and the international medical community in combating this critical problem.
Challenges of Drug Resistance
Gram-negative bacteria pose a major challenge due to their complex cell structures, which protect them from conventional antibiotics. These bacteria frequently cause severe hospital-acquired infections, including urinary tract infections, bloodstream infections, pneumonia, and wound infections. The rise of carbapenem-resistant Gram-negative bacteria has intensified the crisis, rendering critical antibiotics ineffective, prolonging hospital stays, raising treatment costs, and increasing patient mortality.
In India, overuse of antibiotics and high infection rates have made the situation particularly urgent, creating an immediate need for new, effective treatments.
What is Zaynich?
Zaynich is a combined antibiotic therapy, with cefepime (a cephalosporin) targeting bacterial cell walls and zidebactam, a beta-lactam enhancer, inhibiting bacterial resistance enzymes. While cefepime destroys bacterial cell walls to cause cell death, beta-lactamase-producing bacteria typically degrade it, rendering treatment ineffective. Zidebactam protects cefepime from breakdown and boosts its activity by interacting with bacterial penicillin-binding proteins. This dual mechanism enables Zaynich to treat multiple drug-resistant Gram-negative bacteria, including carbapenem-resistant strains.
Effectiveness and Impact
Zaynich shows treatment success rates roughly 20% higher than existing antibiotics, proving highly effective against hospital-acquired pathogens. Medical experts consider it a life-saving option for patients with limited or no alternative therapies.
The development received support from the Biotechnology Industry Research Assistance Council (BIRAC) and other government bodies, highlighting the importance of public-private collaboration in addressing antibiotic resistance. Its successful launch underscores India’s growing leadership in advanced pharmaceutical research and clinical innovation.
Global Significance
Antimicrobial resistance is a leading global health threat, causing millions of infections and deaths annually. The World Health Organization identifies resistance in Gram-negative bacteria as a top priority for new antibiotic development.
Zaynich provides doctors worldwide with a critical tool for managing drug-resistant infections. Its availability is crucial for global healthcare, as resistant infections can easily cross borders. By enabling superior patient outcomes, Zaynich strengthens public health defenses against the growing threat of antibiotic-resistant infections. (Agencies)
